What a month! In May we surpassed our $100,000 USD fundraising goal to accelerate KAND therapeutic development, introduced a new partner: Good Dogg Beverage, welcomed Summer Interns, opened the KAND Conference registration, and even more. Learn more about the progress we’ve made in this Monthly Momentum update.
Read MoreGood Dogg Beverage Partners with KIF1A.ORG to Support Our Mission
KIF1A.ORG Community, We are excited to introduce you to Good Dogg Beverage, a new philanthropic company that makes premium hard seltzer to support causes they care about, like KIF1A.ORG. As a purpose-driven company, Good Dogg Beverage is a rare hard seltzer maker that stands out from the rest. Their goal is to make a positive…
Read MoreKIF1A.ORG Welcomes 2021 Summer Interns from Columbia University
KIF1A.ORG Community, Please help us welcome two interns from the M.A. Program in Biotechnology at Columbia University: Jerry Shen and Michelle Tao! We’re excited to have Jerry and Michelle share their skills and experience with KIF1A.ORG this summer to help advance our mission!
Read MoreKIF1A.ORG Accelerates KAND Research at Gennerich Lab
KIF1A.ORG Community, We’re eager to announce the expansion of our efforts to find treatments for KIF1A-Associated Neurological Disorder (KAND) by partnering with the Gennerich Lab at Albert Einstein College of Medicine in New York. Arne Gennerich, Ph.D., is an active member of the KIF1A Research Network and an expert in molecular mechanisms of microtubule-based motor…
Read MoreKIF1A.ORG Partners with Rarebase to Accelerate Therapeutic Development
KIF1A.ORG Community, KIF1A.ORG is excited to expand our pipeline of therapeutic development projects for KIF1A Associated Neurological Disorder (KAND) through our partnership with Rarebase. Rarebase is a public benefit corporation pioneering a new approach to biotech by partnering with patient communities like ours. They share our sense of urgency and optimism in today’s science to…
Read MoreThe Year in Review: 2020 Impact
Another year has come and gone, and despite the changes and challenges that this year brought for many, the KIF1A.ORG community continued to experience exponential growth thanks to people like you. Real growth. Tangible growth. Growth that will allow THIS generation of individuals living with KIF1A Associated Neurological Disorder (KAND) to realize dreams, gain independence…
Read MoreCoping and Family Box Project
KIF1A.ORG introduces a new program to bring support and comfort to KIF1A superheroes undergoing a medical procedure or recovering from an injury. Read on to learn more about this new resource made possible by a partnership with Ryan’s Case for Smiles and Phillies Charities, Inc.
Read MoreKIF1A.ORG Accelerates KAND Research at Christodoulou Lab
KIF1A.ORG Community, What if KIF1A treatment already existed? It could be on the shelves of your local pharmacy, or a drug created for a related disease like Parkinson’s or epilepsy. Are there FDA-approved treatments for other conditions that could bring relief to KAND patients living with progressive spasticity, uncontrolled seizures or painful neuropathy? We won’t…
Read MoreKIF1A.ORG Accelerates KAND Research with AMRI
KIF1A.ORG Community, Today we’re highlighting the exciting work we’re doing with Albany Molecular Research Inc. (AMRI) to support KIF1A.ORG’s therapeutic development efforts. This project was made possible by a Rising Tides grant awarded by The Child Neurology Foundation to support organizations during the COVID-19 pandemic.
Read MoreKIF1A.ORG Welcomes Charlotte and Aileen to the Team
KIF1A.ORG Community, We are thrilled to introduce you to two new staff members: Charlotte Klinepeter, Administrative Manager, and Aileen Lam, Science Communication Associate! Charlotte and Aileen bring valuable strengths and experiences to the organization and expand our capacity to accelerate our mission.
Read MoreKIF1A.ORG Accelerates KAND Research at Barinka Lab
KIF1A.ORG Community, We’re excited to introduce one of our newest partners, the Bařinka Lab at Institute of Biotechnology of the Czech Academy of Sciences in the Czech Republic! Our partnership will enable the Bařinka Lab to collaborate with HNF Pharma Inc. and The Jackson Laboratory to study a potential drug therapy for KIF1A Associated Neurological…
Read More